Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials

Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials

The usefulness of Gleason score (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2016-04, Vol.27 (4), p.699-705
Hauptverfasser: Fizazi, K., Flaig, T.W., Stöckle, M., Scher, H.I., de Bono, J.S., Rathkopf, D.E., Ryan, C.J., Kheoh, T., Li, J., Todd, M.B., Griffin, T.W., Molina, A., Ohlmann, C.H.
Format: Artikel
Sprache:eng
Schlagworte:
abiraterone acetate
Abiraterone Acetate - administration & dosage
Adult
Aged
Aged, 80 and over
Androstenols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
chemotherapy-naïve
Disease-Free Survival
Double-Blind Method
Gleason score
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Original
post-chemotherapy
Prednisone - administration & dosage
prostate cancer
Prostatic Neoplasms, Castration-Resistant - diagnosis
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The usefulness of Gleason score (
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdv545